<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04547829</url>
  </required_header>
  <id_info>
    <org_study_id>PEG-rhG-CSF</org_study_id>
    <nct_id>NCT04547829</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy</brief_title>
  <official_title>Safety and Efficacy of Pegylated Recombinant Human Granulocyte-colony Stimulating Factor(PEG-rhG-CSF) in Preventing Neutropenia in Children With Tumor After Chemotherapy：A Multi-center, Single Arm Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the safety of PEG-rhG-CSF in the prevention of neutropenia in&#xD;
      children with tumor after chemotherapy, and then evaluate the effectiveness of PEG-rhG-CSF in&#xD;
      preventing neutropenia in children with tumor after chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dosage was determined according to the patient's weight, 100 UG / kg each time; The&#xD;
      method of administration: subcutaneous injection; The time of administration: 24-48 hours&#xD;
      after the end of chemotherapy, once in each chemotherapy cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">May 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of PEG-rhG-CSF in the prevention of neutropenia in children with tumor after chemotherapy</measure>
    <time_frame>From the beginning of observation to the end of observation（6 weeks) of the last enrolled patient</time_frame>
    <description>The incidence and severity of adverse events;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effectiveness of PEG-rhG-CSF in preventing neutropenia in children with tumor after chemotherapy.</measure>
    <time_frame>From the beginning of observation to the end of observation（6 weeks) of the last enrolled patient</time_frame>
    <description>The incidence of grade III / IV ANC reduction in each chemotherapy cycle</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Pediatric Cancer</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegylated recombinant human granulocyte-colony stimulating factor subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated recombinant human granulocyte-colony stimulating factor</intervention_name>
    <description>The dosage was determined according to the patient's weight, 100 UG / kg each time; The method of administration: subcutaneous injection; The time of administration: 24-48 hours after the end of chemotherapy, once in each chemotherapy cycle.</description>
    <arm_group_label>PEG-rhG-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 1)6 years &lt; age &lt; 18 years old, regardless of gender; 2)Tumor patients diagnosed by&#xD;
        histopathology or bone marrow cytology; 3)Patients who have not been treated for the first&#xD;
        time; 4)ECoG score ≤ 2; 5)The expected survival time is more than 8 months; 6)The&#xD;
        hematopoietic function of bone marrow was normal (ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,&#xD;
        Hb ≥ 75 g / L, WBC ≥ 3.0 × 109 / L); 7)Receive high-intensity chemotherapy, such as scccg&#xD;
        lymphoma, CAV / ie, VIP regimen, etc., and expect bone marrow suppression of grade III or&#xD;
        above after chemotherapy.&#xD;
&#xD;
        8)Patient's parent or guardian signs informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with any of the following items will not be enrolled in this study:&#xD;
&#xD;
               1. Local or systemic infection without adequate control;&#xD;
&#xD;
               2. Severe visceral dysfunction;&#xD;
&#xD;
               3. Liver function test: total bilirubin (TBIL), alanine aminotransferase (ALT),&#xD;
                  aspartate aminotransferase (AST) were all higher than 2.5 times of the upper&#xD;
                  limit of normal value; if due to liver metastasis, the above indicators were more&#xD;
                  than 5 times of the upper limit of normal value; renal function test: Serum&#xD;
                  creatinine (CR) &gt; 2 times of the upper limit of normal value;&#xD;
&#xD;
               4. Those who took the same kind of other tested drugs or accepted clinical trials of&#xD;
                  other drugs within 4 weeks before enrollment;&#xD;
&#xD;
               5. Allergic to peg-rhG-CSF, rhG-CSF and other preparations or proteins expressed by&#xD;
                  Escherichia coli;&#xD;
&#xD;
               6. Serious mental illness, affecting informed consent and / or expression or&#xD;
                  observation of adverse reactions;&#xD;
&#xD;
               7. The researcher judged the patients who were not suitable to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yizhuo Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University CancerCenter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yizhuo Zhang</last_name>
    <phone>020-87342459</phone>
    <email>zhangyzh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center,</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junting Huang, Dr</last_name>
      <phone>+8613632483966</phone>
      <email>huangjt@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yizhuo Zhang</investigator_full_name>
    <investigator_title>Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

